Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

Table 1 The primary antibodies used in the study

Antibody	Species	Targeted species	Dilution ratio	Supplier	Catalogue number
β-actin	M	H, M, R	1:1000	CST	3700
PCNA	Rbt	H, M, R	1:2000	PT	10,205–2-AP
Bax	M	H, M, R	1:1000	PT	60,267–1-Ig
Bcl-2	Rbt	H	1:1000	CST	15,071
Caspase 3	Rbt	H, M, R	1:1000	PT	19,677–1-AP
HK2	Rbt	H, M, R	1:1000	PT	22,029–1-AP
PFKL (PFK1)	Rbt	H, M	1:1000	CST	8175
PKM2	M	H, M, R	1:1000	PT	60,268–1-Ig
OXPHOS	M	H, M, R	1:250	MT	MS604
HIF-1α	Rbt	H	1:1000	PT	20,960–1-AP
PPAR-γ	Rbt	H, M, R	1:1000	ABclonal	60,318–1-Ig
Cleaved PARP	Rbt	H	1:1000	CST	5625S
Cleaved PARP	M	M	1:1000	CST	9548S
Ki-67	Rbt	M, R	1:1000	Servicebio	GB111141
LaminA/C	Rbt	H, M, R	1:1000	PT	10,298–1-AP
β-Tubulin	Rbt	H, M, R	1:1000	PT	10,094–1-AP

Abbreviations for the table: H human; M mouse; Rbt rabbit; R rat; CST Cell Signaling Technology (Danvers, MA, USA). PT Proteintech (Chicago, IL, USA). ABclonal Biotechnology (Wuhan, China). MS Mitoscience (St. Louis Park, MN, USA)

ISSN: 1756-9966